Robot model
Stelo
Stelo by Dexcom is a continuous glucose monitor biosensor and the glucose-biometric entry in the cohort, recorded in the biometric form factor as a boundary…
- Manufacturer
- Dexcom
- Form factor
- biometric
- Maturity
- commercial
- Lifecycle
- active
- Deployments
- 1
- Website
- investors.dexcom.com ↗
Overview
Stelo by Dexcom is a continuous glucose monitor biosensor and the glucose-biometric entry in the cohort, recorded in the biometric form factor as a boundary include because glucose is in the biometric definition and Stelo pairs an FDA-cleared sensor with a genuine generative-AI insight layer rather than being a bare sensor readout. Made by DexCom (NASDAQ: DXCM) as a product line separate from its prescription G7 monitors, Stelo is the first-ever FDA-cleared over-the-counter, no-prescription continuous glucose biosensor, cleared via De Novo announced on March 5, 2024 and launched in the US on August 26, 2024 for adults 18 and older who are not on insulin, including people with type 2 diabetes not on insulin and non-diabetic users tracking the impact of diet and exercise, with a 15-day wear and no low-glucose alerts since it is not cleared for problematic hypoglycemia. Its AI augmentation is genuine: Dexcom launched a generative-AI platform for Stelo on Google Cloud's Vertex AI and Gemini, providing personalized Weekly Insights, AI photo meal logging, and up to three personalized daily recommendations drawn from glucose, activity, nutrition, and sleep, which is what tips it from a medical sensor to an in-definition biometric-AI device and fills the glucose cell distinct from the heart-rate and sleep watches and rings. Its FDA clearance makes it the strongest verification anchor of the Wave-2 set, while the marketing claim of being the first generative-AI platform in glucose biosensing is not load-bearing and is not asserted, and its exclusion of low-glucose alerting is recorded as an indication boundary.
Verified vs. claimed
- Maturity stage
- commercial(Commercially deployed with revenue-generating operations.)
- Verified deployments
- 1 deployment on file
- Sources on file
- 5 sources, view all
Key facts
Wear duration
FDA clearance date
US launch date
Target users
AI platform
Price
Pricing model
Availability
Form factor
Specs
Notes
Specs
Battery
Weight kg
Form Factor
Fda clearance
Data & sources
Press releases
3
News coverage
1
Government records
1
5 sources backing this record.View all →
Availability and pricing
- Availability
- Shipping now
- Price
- $89 to $99 (actual sale price)as of 2024-08-26
- Units in field
- Not disclosed
- Sales model
- Not disclosed
- Lead time
- Not disclosed
Pricing
Price status: actual-sale-price = real published price at time of sale; manufacturer-target = vendor target, not yet realized; analyst-estimate = third-party projection, not a vendor figure; not-announced = no price on record.
Prices verified as of Aug 26, 2024
Deployments (1)
- Stelo at Globaloperational
The Stelo is an over-the-counter continuous glucose biosensor that received FDA authorization in March 2024 as the first OTC continuous glucose monitor, operated by Dexcom in San Diego.
Stelo on the deployment map
Where Stelo is verified operating. Explore the deployment map by place and type.
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Specs.fda clearance verifiedVerifiedJun 7, 2026
cleared
- Verified media addedVerifiedJun 4, 2026
Stelo by Dexcom getting started
- Record createdJun 3, 2026
Added to the verified registry
- Price point recorded: $89-$99VerifiedAug 26, 2024
Actual sale price
- Deployment verifiedVerifiedMay 1, 2024
at Global
Deployment-verified media (1)
Dexcom's getting-started guide for Stelo, its over-the-counter glucose biosensor. Stelo is FDA-cleared as the first OTC integrated continuous glucose monitor (2024), for wellness and metabolic-health users not on insulin, distinct from the prescription Dexcom G7.
From deployment: Global
Regulatory filings (2)
Safety record
No incidents on record for Stelo.
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Sources (5)
- https://investors.dexcom.com/news/news-details/2024/Stelo-by-Dexcom-First-Glucose-Biosensor-to-be-Cleared-by-FDA-as-Over-the-Counter/default.aspx
- https://investors.dexcom.com/news/news-details/2024/Dexcom-Launches-the-First-Generative-AI-Platform-in-Glucose-Biosensing/default.aspx
- https://www.medtechdive.com/news/dexcom-gen-ai-feature-stelo-cgm/735918/
- https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K234070
- https://www.stelo.com/en-us/buy-stelo-one-time
Compare Stelo
Common questions
- What is Stelo?
- Stelo by Dexcom is a continuous glucose monitor biosensor and the glucose-biometric entry in the cohort, recorded in the biometric form factor as a boundary include because glucose is in the biometric definition and Stelo pairs an FDA-cleared sensor with a genuine generative-AI insight layer rather than being a bare sensor readout. Made by DexCom (NASDAQ: DXCM) as a product line separate from its prescription G7 monitors, Stelo is the first-ever FDA-cleared over-the-counter, no-prescription continuous glucose biosensor, cleared via De Novo announced on March 5, 2024 and launched in the US on August 26, 2024 for adults 18 and older who are not on insulin, including people with type 2 diabetes not on insulin and non-diabetic users tracking the impact of diet and exercise, with a 15-day wear and no low-glucose alerts since it is not cleared for problematic hypoglycemia. Its AI augmentation is genuine: Dexcom launched a generative-AI platform for Stelo on Google Cloud's Vertex AI and Gemini, providing personalized Weekly Insights, AI photo meal logging, and up to three personalized daily recommendations drawn from glucose, activity, nutrition, and sleep, which is what tips it from a medical sensor to an in-definition biometric-AI device and fills the glucose cell distinct from the heart-rate and sleep watches and rings. Its FDA clearance makes it the strongest verification anchor of the Wave-2 set, while the marketing claim of being the first generative-AI platform in glucose biosensing is not load-bearing and is not asserted, and its exclusion of low-glucose alerting is recorded as an indication boundary.
- How much does Stelo cost?
- Stelo is listed at $89 to $99 on the DEPLOY registry. This is an actual sale price on record.
- Is Stelo actually deployed in the real world?
- Yes. Stelo is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.
- What are the specs of Stelo?
- Stelo's recorded specifications on the DEPLOY registry: Battery: 15 days; Weight: 0.005 kg. See the Specs section for the full sourced set.
- Who makes Stelo?
- Stelo is made by Dexcom, based in San Diego, California, USA, founded in 1999.
- Where is Stelo deployed?
- 1 verified deployment of Stelo is on the DEPLOY registry, including at Global.
- Can you buy Stelo?
- Stelo is available for purchase - a real sale price is on record (see the pricing section for the figure and its source).
- Is Stelo FDA cleared?
- Stelo has 2 regulatory records on the DEPLOY registry: FDA 510(k) clearance (K234070), cleared; FDA 510(k) clearance (K234070), cleared. See the Regulatory filings section for each agency source.
- What are alternatives to Stelo?
- On the DEPLOY registry, comparable biometric robots to Stelo include Butterfly iQ+, Apple Watch, Butterfly AI Ultrasound, Evie Ring (and EvieMED).
- How does Stelo compare to Butterfly iQ+?
- Stelo and Butterfly iQ+ (Butterfly Network · 2 deployments) are both biometric robots on the DEPLOY registry. Stelo has 1 verified deployment on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.
- Is Stelo a top biometric?
- On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Stelo ranks in roughly the top 39% of biometric models tracked by the registry.
- What is Stelo's maturity stage?
- Stelo is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.
- Is Stelo safe?
- Stelo has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.
- What is the Stelo glucose biosensor?
- Stelo is a non-prescription over-the-counter (OTC) glucose biosensor by Dexcom that tracks glucose 24/7. It is an integrated Continuous Glucose Monitor (iCGM) suitable for adults (18+ years) not on insulin. FDA-cleared under 510(k) K234070. No prescription required.
Methodology: Verified · 5 sources (4 primary) · last reviewed 2026-07-18
Verification posture
Verified
High confidence
Review state
Stable
Last reviewed 2026-07-18
Maturity + lifecycle
Maturity stage: commercial
Lifecycle: active
Architectural position
Cohort: biometric
Sub-cohorts: glucose-cell-ai-substance-gradient
Sources by quality tier
- 3
- primary-company-ir
- Company IR disclosure
- 1
- secondary-trade-publication
- Trade publication
- 1
- primary-fda-database
- FDA database
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Stelo.Recent coverage
Stelo in third-party press
Attention vs reality over time
Media mentions per month (area) against verified deployment events (dots). A press spike over a flat deployment line is the hype gap, drawn over time.
In the press
Recent coverage mentioning Stelo from third-party publications. Automatically surfaced; not part of the verified registry record.
Dexcom’s latest executive pay disclosure covers new CEO’s big year
Dexcom has reported the 2025 pay packages for executives including former CEO Kevin Sayer and new CEO Jake Leach, who was promoted twice last year and unexpectedly stepped into…
Will Giving Everyone a Blood Sugar Monitor Lead to Better Health Outcomes? Maybe, But Only If We Tell People What to Do With The Info
Last year, I used a continuous glucose monitor (CGM) for the first time, and it completely changed how I eat. After a couple of weeks using an over-the-counter Stelo CGM, […]
Dexcom - Wikipedia
Wikipedia overview of Dexcom: founded 1999, IPO 2005, products include G4, G5, G6, G7, and Stelo CGM systems, revenue $4.66B in 2025.
Dexcom Stelo: the 200 Best Inventions of 2024
Time Magazine named Dexcom Stelo's over-the-counter glucose monitor one of the year's best inventions.
Dexcom to join the NASDAQ-100 Index beginning April 20, 2020
Dexcom joined the Nasdaq-100 Index on April 20, 2020, replacing American Airlines Group.
FDA authorizes first fully interoperable continuous glucose monitoring system
FDA approved the Dexcom G6 as the first fully interoperable CGM system, streamlining the review pathway for similar devices.
Machine-readable surfaces
- Markdown mirror: /models/stelo.md
- JSON-LD: embedded in this page’s head
- REST API: /v1/models/d3f4598c-3c0a-4a99-a235-d0d94eebf947
- Revision history: /models/stelo/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Buyer-facing pricing: deploy.report/price/stelo
Video
Time with just the 3 of us is rare. These two are extra silly when they’re together. She’s definitely Dad’s mini me. Enjoy this short cute moment we had. 💕 #
Découvrez à quel point il est facile d’insérer le capteur Dexcom G6 et de fixer l’émetteur. LBL017777 Rev001 FR
Dress up your devices with any of ExpressionMed's 200+ tape designs! #expressionmed #dexcom #omnipod #cgm #pump #diabetes
*(EPISODE 6 - Captain Sandy moved her insulin pump, OmniPod, back to her arm. She keep hitting it when she placed it on her lower back. She hit it yesterday get
*(EPISODE 7 - Captain Sandy says it's Casual Friday, yeah! She is going to tackle 5 meetings today. Then after that, hopefully won't have to take on any comic b
#SugarPixel shows your #CGM glucose reading in a neat, pixelized display! Compatible with #dexcom and #libre. Also features auditory and vibration alerts. Made
DexCom CEO Kevin Sayer discusses the impact data sharing can have on medicine, telling CNBC's Jim Cramer that it represents the "next frontier" for the industry
Captain Sandy uses her phone to manage her type 1 diabetes. She can read her blood sugar levels from her DexcomCGM on her app on her phone. Her Omnipod insulin
What company holds the future of diabetes care? Is it Medtronic the makers of the 670g insulin pump? Dexcom the makers of the G6 continuous glucose monitor? Tan
Senior Design Day Video for San Diego State University Mechanical Engineering Senior Design Capstone Program. To learn more, go to https://mechanical.sdsu.edu/
San Diego State University Mechanical Engineering Senior Design Capstone Program https://mechanical.sdsu.edu/
Glycemia sensors' true feedback #diabetes #t1d #sensor #medtronic #libre #dexcom what the sensors say by themselves:) this is the joke but it's actually true
In this episode, we're at the nexus of fashion and tech, showcasing innovations reshaping our interaction with clothing and health. We spotlight Zyler's eco-con
Reality vs attention
Stelo draws attention at the 69th percentile but verifies reality at the 46th percentile among biometric robots. Hype Gap +23.2, 4th widest among biometric robots.
6-month trend
Analysis
Thin deployment record; scale validation still in progress.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Jul 19, 2026